A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival (PFS)
PFS is the primary outcome for the Phase 2 portion of the study. PFS is measured from the date of randomization until the first radiographic documentation of objective progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) or death from any cause.
23 months
No
ClinicalTrials@ ImClone.com
Study Director
ImClone LLC
United States: Food and Drug Administration
14055
NCT01185964
October 2010
December 2014
Name | Location |
---|---|
ImClone Investigational Site | Denver, Colorado 80262 |
ImClone Investigational Site | New York, New York 10021 |
ImClone Investigational Site | St. Charles, Missouri 63301 |
ImClone Investigational Site | Bakersfield, California 93309 |
ImClone Investigational Site | Jacksonville, Florida 32207 |
ImClone Investigational Site | Atlanta, Georgia 30318 |
ImClone Investigational Site | Decatur, Illinois 62526 |
ImClone Investigational Site | Minneapolis, Minnesota 55416 |
ImClone Investigational Site | Cleveland, Ohio 44134 |
ImClone Investigational Site | Greenville, South Carolina 29605 |
ImClone Investigational Site | Memphis, Tennessee 38104 |
ImClone Investigational Site | Dallas, Texas 75230 |
ImClone Investigational Site | Green Bay, Wisconsin 54307 |
ImClone Investigational Site | Winston-Salem, North Carolina 27103 |
ImClone Investigational Site | Tucson, Arizona 85712 |
ImClone Investigational Site | Seattle, Washington 98104 |